Skip to content

Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?

Louisa Degenhardt, Wayne Hall, Michael T. Lynskey, John Joseph McGrath, Jennifer McLaren, Bianca Calabria, Harvey Whiteford, Theo Vos

PLoS Medicine September 28, 2009 DOI: 10.1371/journal.pmed.1000133 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Commentary Peer reviewed
Topics Cannabis
Citations 48
Key points Argues that the GBD comparative risk assessment should include attribution of psychosis to cannabis use, because the observational evidence is as good as that for many other included risk factors, psychotic disorders involve substantial unavertable disability, and cannabis use is a potentially preventable exposure.

Abstract

N Comparative risk assessments estimate the proportion of a disease that can be attributed to a particular risk exposure and are important guides for health planning.N In observational studies, there has been consistent evidence that cannabis use is associated with an increased risk of schizophrenia and more generally, psychosis.N There is debate about whether such observational evidence is sufficient to infer that cannabis use is a contributory cause of psychosis.N Given the controversy, should the comparative risk assessment in the current revision of the Global Burden of Disease (GBD) include an attribution of psychosis to cannabis use?N We argue that the risk assessment should be included because the evidence is as good as that for many other risk factors included in the GBD, psychotic disorders are associated with substantial unavertable disability, and cannabis use is a potentially preventable exposure.

Citations in the library

Explore topics